BACKGROUND: Metastatic basal cell carcinoma (BCC) is a rare but life-threatening condition. Prior estimates of overall survival (OS) from time of diagnosis of distant metastasis to death are approximately 8-14 months. However, these estimates are based on analyses of case reports published prior to 1984. OBJECTIVES: To assess an updated OS in patients with metastatic BCC at a single academic institution. METHODS: Using patients seen from 1997 to 2011, a retrospective chart review was performed on biopsy-confirmed cases of distant metastatic BCC at Stanford University School of Medicine. Kaplan-Meier analysis was used to determine OS and progression-free survival (PFS). RESULTS: Ten consecutive cases of distant metastatic BCC were identified. Median OS was 7·3 years [95% confidence interval (CI) 1·6-∞]; median PFS was 3·4 years (95% CI 1·1-5·2). CONCLUSIONS: Our findings suggest that OS in patients with distant metastatic BCC may be more favourable than previously reported.
BACKGROUND:Metastatic basal cell carcinoma (BCC) is a rare but life-threatening condition. Prior estimates of overall survival (OS) from time of diagnosis of distant metastasis to death are approximately 8-14 months. However, these estimates are based on analyses of case reports published prior to 1984. OBJECTIVES: To assess an updated OS in patients with metastatic BCC at a single academic institution. METHODS: Using patients seen from 1997 to 2011, a retrospective chart review was performed on biopsy-confirmed cases of distant metastatic BCC at Stanford University School of Medicine. Kaplan-Meier analysis was used to determine OS and progression-free survival (PFS). RESULTS: Ten consecutive cases of distant metastatic BCC were identified. Median OS was 7·3 years [95% confidence interval (CI) 1·6-∞]; median PFS was 3·4 years (95% CI 1·1-5·2). CONCLUSIONS: Our findings suggest that OS in patients with distant metastatic BCC may be more favourable than previously reported.
Authors: V Alonso; A Revert; C Monteagudo; J M Martin; A Insa; I Pinazo; J Ferrer; E Jorda Journal: J Eur Acad Dermatol Venereol Date: 2006-07 Impact factor: 6.166
Authors: Howard W Rogers; Martin A Weinstock; Ashlynne R Harris; Michael R Hinckley; Steven R Feldman; Alan B Fleischer; Brett M Coldiron Journal: Arch Dermatol Date: 2010-03
Authors: Aleksandar Sekulic; Michael R Migden; Anthony E Oro; Luc Dirix; Karl D Lewis; John D Hainsworth; James A Solomon; Simon Yoo; Sarah T Arron; Philip A Friedlander; Ellen Marmur; Charles M Rudin; Anne Lynn S Chang; Jennifer A Low; Howard M Mackey; Robert L Yauch; Richard A Graham; Josina C Reddy; Axel Hauschild Journal: N Engl J Med Date: 2012-06-07 Impact factor: 91.245
Authors: Katharine E Jong; David P Smith; Xue Q Yu; Dianne L O'Connell; David Goldstein; Bruce K Armstrong Journal: Med J Aust Date: 2004-06-21 Impact factor: 7.738
Authors: J T Lear; M R Migden; K D Lewis; A L S Chang; A Guminski; R Gutzmer; L Dirix; P Combemale; A Stratigos; R Plummer; H Castro; T Yi; M Mone; J Zhou; U Trefzer; M Kaatz; C Loquai; R Kudchadkar; D Sellami; R Dummer Journal: J Eur Acad Dermatol Venereol Date: 2017-11-06 Impact factor: 6.166